Record 040 · Therapeutics · 2018
50%18.40.X
Rubedo Life Sciences
Rubedo Life Sciences
“Senolytics designed to hit the right senescent cell, not every old cell.”
Rubedo’s GPX4/senescence programs try to be selective. A second-wave senolytic company after the first ones stumbled.
Senolytics after the hangover.
Series A. Filed from the Top Tier Impact landscape.
- Selective senolytics
- GPX4-adjacent programs
The right senescent cell.
